Diglyceride Kinase Iota: A Promising Drug Target for Various Diseases

Target Name: DGKI

NCBI ID: G9162

DGKI

Diglyceride Kinase Iota: A Promising Drug Target for Various Diseases

Diglyceride kinase iota (DGKI) is a protein that is expressed in various tissues throughout the body, including muscle, heart, and brain. It plays a role in the regulation of lipid metabolism, which is the process by which the body produces and consumes different types of fats.

DGKI is a key enzyme that is involved in the breakdown of triglycerides, which are the main type of fat found in the blood. This process occurs in the liver, where DGKI is localized to the mitochondria. When triglycerides are broken down, DGKI is converted into the active form, which is then used by the body for energy.

One of the unique features of DGKI is its ability to act as a drug target. DGKI has been shown to be a promising target for the development of new treatments for various diseases, including heart disease, diabetes, and obesity.

One of the reasons why DGKI is considered a drug target is its involvement in the regulation of lipid metabolism. There is much research evidence that DGKI plays a key role in the production and breakdown of triglycerides, which are the primary source of the bad cholesterol, low-density lipoprotein (LDL) cholesterol.

Additionally, DGKI has been shown to be involved in the regulation of lipid oxidation, which is the process by which the body produces reactive oxygen species (ROS) that can damage cellular components and contribute to the development of various diseases, such as heart disease and cancer.

Another potential mechanism by which DGKI may be involved in the development of certain diseases is its role in the regulation of cellular signaling pathways. DGKI has been shown to be involved in the regulation of several signaling pathways, including the TGF-β pathway, which is involved in the development and maintenance of tissues, and the PI3K/Akt pathway, which is involved in the regulation of cellular signaling pathways.

DGKI has also been shown to be involved in the regulation of cellular responses to stress, which is a critical factor in the development of many diseases, including heart disease and diabetes.

In conclusion, DGKI is a protein that plays a critical role in the regulation of lipid metabolism and cellular signaling pathways. Its involvement in these processes makes it an attractive target for the development of new treatments for various diseases. Further research is needed to fully understand the role of DGKI in disease development and to develop effective strategies for the treatment of its associated conditions.

Protein Name: Diacylglycerol Kinase Iota

Functions: Diacylglycerol kinase that converts diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and regulates the respective levels of these two bioactive lipids (PubMed:9830018, PubMed:23949095). Thereby, acts as a central switch between the signaling pathways activated by these second messengers with different cellular targets and opposite effects in numerous biological processes (Probable). Has probably no preference for any of the diacylglycerols in terms of the acyl chain composition, especially for the acyl chain at the sn-2 position (PubMed:9830018). By controlling the diacylglycerol/DAG-mediated activation of RASGRP3, negatively regulates the Rap1 signaling pathway. May play a role in presynaptic diacylglycerol/DAG signaling and control neurotransmitter release during metabotropic glutamate receptor-dependent long-term depression (By similarity)

The "DGKI Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DGKI comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets